Bristol-Myers Squibb and Nektar Therapeutics have signed a deal to develop and commercialise the latter’s lead immuno-oncology programme, NKTR-214, in combination with other anticancer therapies, on the back of the success of a previous clinical trials pact. http://www.pharmatimes.com/news/bms,_nektar_to_jointly_develop,_commercialise_immunotherapy_combo_1222262
The trade body for generics and biosimilar manufacturers warns of barriers to entry for its products. https://www.biopharmadive.com/news/industry-touts-savings-potential-of-generics-and-biosimilars/517098/
Read recent commentaries about drug-cost issues. https://khn.org/morning-breakout/perspectives-cms-takes-steps-to-ensure-patients-benefit-from-negotiated-discounts/
Biogen has reported record biosimilar revenues and says it intends to increase its share in Samsung Bioepis. https://www.biopharma-reporter.com/Article/2018/01/26/Biogen-looking-to-up-its-stake-in-Samsung-biosimilar-JV
Intense competition in the diabetes drugs market has pushed manufacturers to search for ways to gain an edge, including value-based deals with payers. https://www.biopharmadive.com/news/boehringer-strikes-jardiance-outcomes-deal-with-prime-pbm/516026/
(Reuters) – A costly new Roche Holding AG drug to treat the bleeding disorder hemophilia A could significantly reduce healthcare expenses for certain patients, a draft report from an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.
Novartis says it will scale up the use of Apple ResearchKit in clinical trials, as part of its efforts to bring about digital transformation.
The post Novartis and Apple to scale up clinical trial collaboration appeared first on Pharmaphorum. https://pharmaphorum.com/news/researchkit-novartis-apple-scale-clinical-trial-collaboration/
France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases. The deal announced Monday is the latest such move in a pharmaceutical industry that’s seeing increasing interest in rare diseases. http://www.topix.com/business/pharmaceuticals/2018/01/frances-sanofi-buys-us-hemophilia-specialist-bioverativ?fromrss=1
Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. http://www.worldpharmanews.com/novartis/4264-sandoz-announces-exclusive-global-collaboration-with-biocon-on-next-generation-biosimilars
When Spark Therapeutics announced last week an $850,000 price for its gene therapy Luxturna, some critics held it up as the latest example of an expensive new treatment that could break the bank for the healthcare system. But at the J.P. Morgan Healthcare conference this week, it was clear that sentiment is rapidly changing. https://www.fiercepharma.com/financials/payers-point-to-spark-s-gene-therapy-as-a-model-for-innovative-pricing-plans